Sort by
Keyphrases
Methylation
100%
Interindividual Heterogeneity
100%
Glioblastoma
100%
Molecular Heterogeneity
100%
Tumor
75%
Intratumoral Heterogeneity
75%
DNA Methylation (DNAm)
50%
Molecular Classification
50%
Copy number Variation
50%
Phylogeny
50%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
50%
MGMT Promoter Methylation
50%
Multiple Tissues
25%
Epigenetics
25%
Copy number Analysis
25%
Molecular Diversity
25%
Molecular Targets
25%
High Variability
25%
Sub-volume
25%
Newly Diagnosed
25%
Therapeutic Target
25%
Phylogenetic Analysis
25%
DNA Copy
25%
Treatment Resistance
25%
Tumor Development
25%
Targeted Therapy
25%
Treatment-naïve
25%
Glioma
25%
Poor Clinical Outcomes
25%
Cyclin-dependent Kinase 4 (CDK4)
25%
Pilocytic Astrocytoma
25%
Platelet-derived Growth Factor Receptor (PDGFR)
25%
Tissue Biopsy
25%
Predominant Subtype
25%
Heterogeneous Methylation
25%
Methylation Classifier
25%
Illumina MethylationEPIC Array
25%
Epigenetic Heterogeneity
25%
Publicly Available Data
25%
Tumor Stage
25%
Biochemistry, Genetics and Molecular Biology
Methylation
100%
Copy-Number Variation
60%
Cladistics
60%
Promoter Region
40%
DNA Methylation
40%
Epidermal Growth Factor Receptor
40%
Cyclin Dependent Kinase Inhibitor 2A
40%
Genetics
20%
Epigenetics
20%
Platelet Derived Growth Factor Receptor Alpha
20%
Targeted Therapy
20%